Santoni, M.; Massari, F.; Bracarda, S.; Procopio, G.; Milella, M.; De Giorgi, U.; Basso, U.; Aurilio, G.; Incorvaia, L.; Martignetti, A.;
et al. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics 2021, 11, 138.
https://doi.org/10.3390/diagnostics11010138
AMA Style
Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A,
et al. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics. 2021; 11(1):138.
https://doi.org/10.3390/diagnostics11010138
Chicago/Turabian Style
Santoni, Matteo, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti,
and et al. 2021. "Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?" Diagnostics 11, no. 1: 138.
https://doi.org/10.3390/diagnostics11010138
APA Style
Santoni, M., Massari, F., Bracarda, S., Procopio, G., Milella, M., De Giorgi, U., Basso, U., Aurilio, G., Incorvaia, L., Martignetti, A., Rizzo, M., Cartenì, G., Grande, E., Matrana, M. R., Crabb, S. J., Vau, N., Sorgentoni, G., Cimadamore, A., Montironi, R.,
& Battelli, N.
(2021). Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics, 11(1), 138.
https://doi.org/10.3390/diagnostics11010138